Problem
Metabolically-inefficient energy sources
Obesity
Obesity is the first cause of preventable deaths worldwide and has tripled since 1975.
It is a major risk factor for non-communicable diseases such as: cardiovascular disease, diabetes, joint disease, and some cancers.
Type-2 Diabetes / Insulin resistance
Insulin resistance is the main cause of type 2 diabetes and is The most critical patho-physiologic aspect linking obesity and cardiometabolic diseases. It is an impairment of insulin action on insulin-sensitive tissues characterized by decreased glucose access in muscles and an increased neoglucogenesis in the liver, resulting in fasting as well as postprandial hyperglycemia.
Solution
Dicarboxylic acids (DiCarbs®)
Jemyll provides a new, low-caloric, highly metabolically efficient family of nutrients – dicarboxylic acids, or DiCarbs®.
DiCarbs are a new energy substrate. They are a non-fat, non-carbohydrate source that provides their same metabolic benefits (energy) but prevent their metabolic pitfalls (increased body weight and/or hyperglycemia). DiCarbs enable people to get energy without leading to increased fat mass or causing increased blood sugar.
DiCarbs are also intended for active or athletic people who want energy that does not lead to increased weight or blood glucose levels
Jemyll’s expertise
Biosynthesis and bioproduction of DiCarbs for nutrition
Competitive Advantage
We have rights over several DiCarbs production methods and have the ability to provide pure supply at a large-scale.
A team of experts
We have formed a team of world leaders in nutrition and the study of DiCarbs
Team
Grant Ferrier
President, Chief Investment Officer
He is the CEO of Nutrition Capital Network, has substantial experience in fundraising and wide expertise in advising nutrition companies.
Read more
Timothy S. Avila
CEO
An energetic and knowledgeable scientist and business man, he is an expert in dicarboxylic acids. He has extensive commercialization and distribution experience.
Read more
Geltrude Mingrone
Scientific Advisory Board
She has pushed forward the boundaries of metabolic medicine for the last 30 years and is among the most recognised researchers in metabolic medicine and diabetes research of our time. She is the world-leading expert in the study of dicarboxylic acids for obesity and related metabolic diseases.
Read more